Home > Healthcare > Biotechnology > Biotechnology R&D > Mycoplasma Testing Market

Mycoplasma Testing Market Size

  • Report ID: GMI8300
  • Published Date: Feb 2024
  • Report Format: PDF

Mycoplasma Testing Market Size

Mycoplasma Testing Market was valued at around USD 909.5 million in 2023 and is estimated to register over 11.9% CAGR between 2024 and 2032. Mycoplasma testing involves a series of laboratory techniques designed to detect the presence of mycoplasma bacteria in various biological samples, particularly cell cultures used in research, biomanufacturing, and clinical applications. Mycoplasma is unique bacteria that lacks a cell wall, making them resistant to many antibiotics and difficult to detect using traditional staining methods.


Common testing methods include PCR, enzymatic assays, and direct culture. The increase in cell culture contamination, including mycoplasma contamination, poses significant challenges to research and biomanufacturing processes. For instance, as per estimates, over 10% of all cell cultures are believed to be tainted with mycoplasma species, underscoring the necessity of regular testing to guarantee the purity of cultures. Thus, as contamination rates rise, there's a corresponding need for robust mycoplasma testing methods to identify and mitigate contamination risks promptly.


Furthermore, increasing research and development activities are driving significant expansion within the mycoplasma testing market. With a rising demand for dependable and effective testing techniques such as nucleic acid tests, microbial culturing, and PCR technologies, underscores the importance of innovation in meeting evolving industry needs.


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for mycoplasma testing was valued at around USD 909.5 Million in 2023 and is estimated to reach over USD 2.5 billion by 2032, driven by the rising contamination rate and increasing R&D activities.

Kits & reagents segment held a robust market share in 2023 and is estimated to account for USD 1.4 billion by 2032, owing to their pivotal role in mycoplasma testing, offering standardized protocols, streamlined workflows, and increased accuracy.

North America mycoplasma testing industry held a significant revenue share of 40.6% in 2023 and is predicted to witness substantial growth through 2032, driven by increasing government investment to produce new active pharmaceutical ingredients (APIs).

Becton, Dickinson, and Company (BD), Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Creative Bioarray, Eurofins Scientific, InvivoGen, Lonza Group AG, Merck KGaA, Minerva Biolabs GmbH, PromoCell GmbH are some of the major industry contenders.

Mycoplasma Testing Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 13
  • Tables & Figures: 348
  • Countries covered: 22
  • Pages: 205
 Download Free Sample